Our Therapeutic Areas
Gilead is committed to advancing care for people around the world, by bringing forward medicines in areas of unmet medical need. We do this through internal research and development, as well as through collaborations with academic and industry partners.
Since 1987, Gilead has commercialized more than 25 innovative medicines, helping to transform treatment for people living with diseases such as HIV, viral hepatitis, cancer and other conditions.
Gilead has helped transform care for people living with and at risk for HIV, pioneering inventions that were once thought impossible – the first single tablet regimen to treat HIV and the first antiretroviral for pre-exposure prophylaxis (PrEP) medicine to reduce the risk of acquiring HIV infection.
Our work in HIV continues to span the full continuum of HIV care – from prevention to treatment to working toward the goal of a cure. We are committed to a goal of offering long-acting options that can help address the differentiated needs and preferences of the diverse range of people living with and at risk for HIV.
Beyond the science, we collaborate with partners to help address the root causes driving the HIV epidemic. We believe that anyone living with HIV, and those at risk of infection, should benefit from the latest scientific innovations and have access to medicines.
Hepatitis C, B, and D Viruses
With the same tenacity, innovation and focus that drove our work in HIV, we delivered four curative treatments for chronic hepatitis C virus in less than four years. Today, more than 4 million people have been prescribed our HCV medicines and we continue to reach more people around the world. We have also been on the front lines of transforming care for people with chronic hepatitis B virus for 20 years, and are actively pursuing multiple pathways toward a possible cure. In 2021, through the acquisition of MYR GmbH, we built on our strength in this area by adding a first-in-class treatment in the European Union* for chronic hepatitis delta virus.
*Conditionally approved in Europe
Innovating to Treat COVID-19
When the COVID-19 outbreak began to emerge, we responded quickly to advance our then-investigational antiviral which had shown potential against other coronaviruses in laboratory and preclinical experiments, deploying decades of antiviral expertise and significant internal resources to help patients and communities working to ease the burden of the pandemic. Today, more than 10 million people globally have received our COVID-19 treatment. Gilead also signed non-exclusive voluntary licensing agreements with generic manufacturers to further expand supply of the product for distribution in 125+ countries, nearly all of which are resource limited.
Improving Outcomes for People Living with Cancer
Significant investments have been made by Gilead to add to our oncology portfolio. Our approach covers a broad range of tumor types, including hematological malignancies and solid tumors. We are working to deliver these medicines to patients in need as quickly as possible.
We are building a diverse pipeline with our first-in-class, ADC molecule in breast cancer. Research is ongoing in multiple other solid tumors.
Our colleagues at Kite are responsible for the research, development and commercialization of our cell therapies.
A Historical Commitment Against Invasive Fungal Infections
For 30 years, Gilead has been invested in the treatment of invasive fungal infections, in particular aspergillosis, candidiasis, visceral leishmaniasis (VL) and cryptococcal meningitis. Gilead continues to work to improve access to antifungal treatments for all people in need.